A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma
Latest Information Update: 04 Apr 2025
At a glance
- Drugs Nivolumab (Primary) ; Vidutolimod (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Checkmate Pharmaceuticals
- 23 Oct 2024 Status changed to discontinued due to business decision
- 22 Feb 2024 Status changed from active, no longer recruiting to completed.
- 01 Feb 2024 Planned End Date changed from 6 Oct 2024 to 5 Feb 2024.